Share LinkedIn Email Copy Link The Swiss company’s monoclonal antibody Nemluvio is also undergoing regulatory review for atopic dermatitis, which is a potentially larger market for the first-in-class IL-31 blocker.Read more about this post on Biospace
EndPoints Pfizer ends work on Sangamo’s hemophilia gene therapy, crushing biotech’s hopesDecember 31, 2024
EndPoints Despite mixed data in Alzheimer’s agitation, Axsome will still seek FDA approvalDecember 30, 2024